To describe the direct costs related to warfarin/apixaban treatment
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
CHA2-DS2-VASc Score at Baseline
Timeframe: Baseline (from retrospective data retrieved in the study)
HAS-BLED Score at Baseline
Timeframe: Baseline (from retrospective data retrieved in the study)
CHA2-DS2-VASc Score at Month 6
Timeframe: Month 6 (from retrospective data retrieved in the study)
HAS-BLED Score at Month 6
Timeframe: Month 6 (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Number of Outpatient Visits During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Outpatient Visits During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Number of International Normalized Ratios (INR) Measurements During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of INR Measurements During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Dosage of Warfarin and Apixaban at the Initiation of the Treatment
Timeframe: Baseline (from retrospective data retrieved in the study)
Dosage of Warfarin and Apixaban During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Medication During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Number of Hospital Admissions
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Hospital Admissions During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Number of Diagnostic Procedures
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Type of Ischemic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Ischemic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized With Major Hemorrhagic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Type of Minor Hemorrhagic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Major Hemorrhagic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Minor Hemorrhagic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Number of Participants With Other Adverse Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Other Adverse Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Who Died (Treatment-Related) During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)